340 Index Name Paper ref. Name Paper ref. Jensen, KG FC07.4.5 Jensen, SA Tue 480 Jeon, K-J Mon 065, Tue 324, Tue 323, Mon 066 Jeong, HY Wed 416 Jeppesen, P FC06.2.5 Jeppesen, P Wed 070 Jespersen, T FC06.3.5 Jessen, N FC05.2.6, Mon 154 Jesus-Sandoval, R Tue 025 Jetter, A Mon 315, Mon 384 Jevtic, M Tue 091 Jezova, D Tue 113 Jha, S W01.2.4 Jhaveri, D W01.2.4 Ji, C Wed 429 Ji, Y Mon 470 Jiaang, W-T Mon 158 Jian, Y Mon 433 Jiang, F Mon 194, Wed 219, Tue 285 Jiang, H-K Tue 187, Tue 186, Thu 277 Jiang, L Wed 267 Jiang, M Wed 378 Jiang, N FC16.3.1, Wed 379, Thu 432 Jiang, P-S Thu 199 Jiang, T FC18.4.5 Jiang, X-P Mon 470 Jiang, Y Tue 441 Jiang, Y-Y Mon 265 Jievaltas, M Tue 329 Jimenez-Altayo, F Wed 268 Jimenez-Flores, JR Tue 150 Jiménez-Serranía, M-I Tue 088, Tue 089 Jin, F Thu 186 Jin, H Tue 286, Thu 186 Jin, H-O Tue 427 Jin, M-W FC12.3.5 Jin, X Thu 261 Jin, Y Wed 322 Jindal, R FC09.5.5 Jing, F Tue 173, Tue 325 Jing, W-B Mon 172 Jingami, H FC11.1.4 Jinsheng, G Wed 363 Jiron, M Mon 390 Jirón, M Tue 326 Mon 136, Tue 164 Joannides, R Wed 207, Mon 191 Jockers, R FC11.3.4, Thu 028, Thu 055, Thu 078 Jõgi, K FC10.3.6 Johansen, LD FC11.5.1 Johansson, L Thu 051 Johansson, S Thu 239 Johns, EJ FC05.1.5 Johns, S Tue 327 Johnsen, SP FC04.2.7 Johnson, I Wed 238 Johnson, Ian Wed 269 Johnson, MS Wed 088 Johnson, O Wed 149 Johnson, RP Wed 239 Johnson, TA FC18.4.2 Johnson, T FC10.3.5 Jokela, H Mon 215 Jones, B Tue 136 Jones, R Wed 270 Jönsson, Siv FC07.4.4 Jorge, ARC Thu 374, Wed 297 Jørgensen, FS Wed 066 Jørgensen, H Mon 346, Tue 358 Jørgensen, M Wed 241, Wed 380 Joseph, J Mon 443 Joshi, C FC16.1.6 Joshi, S YI.05, Wed 315 Joskova, M Mon 293 Jost, N Mon 100 Jouanjus, É FC04.3.5 Jovanoviæ, N Wed 398 Jovanovic, D Tue 321 Jovanovic, I FC10.1.6 Jové, J Mon 141 Jovic, N Wed 009 Judas, F Tue 257 Jürgenliemk, G FC16.1.5 Jürgens, G FC09.2.4 Jugovic, VM Wed 435 Juhl, K Mon 046 Jun, D Tue 343, Tue 448 Jun, R Tue 158 Jung, I-S Tue 352 Jung, J Mon 068 Jungke, P Wed 417 Juricic, D FC01.3.7, Mon 135, Tue 328 Jurkat-Rott, K FC12.2.3 Juslin, S Tue 283 Juvonen, T Tue 166 Käär, R FC10.3.6 Kaboutari, J Wed 301 Kacevska, M W06.3 Kadam, V Tue 131, Mon 166 Kadoi, H Mon 416 Kadurin, I FC03.2.4 Kadyrova, D Tue 079 Käenmäki, M Wed 071 Kagawa, Y Tue 484 Kagota, S Tue 143, Tue 067, Wed 271, Thu 320 Kahlon, N Tue 387 Kaila, M Mon 328 Kaipiainen-Seppänen, O FC09.2.5 Kajioka, S Thu 038 Kakefuda, K Thu 406 Kalekou, H Mon 297 Kalenic, S Mon 373 Kales, A Thu 214 Kales, AJ Mon 316 Kalikstad, B Wed 014, Wed 015 Kalin, N Thu 410 Kalinina, TS Wed 187, Mon 422 Kaliszan, R Mon 197 Kalkan, S Tue 449, Tue 450, Tue 366, Mon 474 Kalliokoski, A Tue 363 Kallioniemi, O Mon 410, Tue 436 Kalokasidis, K Mon 300 Kalvinsh, I Mon 429 Kamal, M Thu 078, Wed 072 Kamataki, A Thu 248
Name Paper ref. Name Paper ref. Kamatani, N W23.2 Kamath, S FC04.3.7 Kamei, J Tue 234 Kamerman, P Tue 001 Kaminska, E Thu 174 Kaminski, P FC08.2.5 Kamisaki, Y Wed 186 Kamiuchi, S Wed 266, Thu 227 Kamiya, A Mon 309, Thu 402 Kanai, A FC08.3.2 Kanai, T Thu 263 Kanaoka, D FC03.2.5 Kandrotaite, K Tue 329 Kane, K Mon 211 Kane, S Wed 292 Kaneko, S Tue 055, Thu 108 Kaneko, T Tue 126, FC13.2.5 Kaneko, Y Tue 136 Kang, CY Mon 270 Kang, F Thu 116 Kang, M FC12.1.5 Kang, Y Thu 350 Kang, YJ Thu 116 Kanjuh, V Thu 324, Wed 103 Kanno, S-I Mon 025 Kanters, JK Tue 303 Kapai, N Thu 417 Kapanadze, KT Mon 216 Kapic, E Wed 199 Kapitsa, I Mon 462 Kaplan, T W02.2.7 Kaplinskiy, S FC06.1.6 Kapoor, A FC18.3.6 Kapucu, A Tue 461 Kapur, S FC17.3.1 Karajeva, N Tue 253 Karaman, M Mon 170 Karasiewicz, M Thu 174 Karasova, JZ Tue 074 Karatassas, A Mon 102 Karbwang-Laothavorn, J FC01.3.2 Kargi, A Tue 411 Kargl, J FC11.1.6, Wed 073 Karhi, T Mon 256 Karimi, G Mon 230 Karimollah, A Wed 418 Kariyazono, H Tue 167 Karkoulias, G Wed 074 Karlsson, MO FC07.2.2 Karonen, T Tue 330 Karsdal, MA W26.2, W26.4 Kartal, M Wed 312 Kasabova, L Tue 128 Kasai, A Mon 416, Mon 435, Mon 440, Wed 067, Wed 075 Kasamatsu, R Mon 243 Kashaf, SS Mon 231 Kashanian, M FC01.3.5 Kashimoto, T Tue 477 Kasiotis, K Tue 457 Kassa, J Tue 343 Kast, R Thu 091 Kastratovic, DA Wed 435 Katafuchi, T Wed 141 Katakam, P FC05.1.6 Katano, Y Mon 178 Katayama, Y Wed 263 Katende-Kyenda, NL Mon 026 Katisart, T Mon 086 Katiskalahti, T Mon 144 Kato, M Tue 166 Kato, S FC18.4.3, Mon 335 Katoh, Y Tue 144 Katramadou, M Tue 457 Katryniok, C Mon 317 Katsiki, N Mon 143 Katsoulieris, E Mon 157 Katsouni, E Thu 431 Kattamuri, V Mon 264 Kattige, V W03.2 Katugampola, S Mon 393, Tue 372, Wed 020 Kauffman, M Mon 280 Kaulambaeva, I Thu 336 Kaunitz, JD W02.1.5 Kauppi, M FC09.2.5 Kaur, H FC09.5.5 Kaur, St FC01.3.6 Kaushal, S FC01.3.6 Kautiainen, H FC09.2.5 Kawabata, A FC03.2.5, Tue 263, Tue 077, Mon 243, Mon 250 Kawada, K Tue 376 Kawahara, K Thu 331 Kawahara, R Mon 335 Kawakami, J Tue 484, Tue 491 Kawamoto, E Mon 292 Kawamoto, K Mon 101 Kawamura, E Thu 109 Kawanishi, C Wed 422, Wed 415 Kawanishi, T Tue 168 Kawasaki, H Mon 174, Tue 154, Thu 261, Tue 415, Wed 413, Wed 424 Kawasaki, T Mon 093, Tue 060 Kawazoe, K Wed 278 Kaya, A FC11.3.2, Thu 049 Kaya, AI FC11.3.2 Kaygisiz, B Wed 420 Kayiwa, J FC01.4.5 Kaytanlioglu, L Tue 142 Kazakova, FF Thu 096 Kazakova, RR Thu 096 Kazemi, M Tue 165 Kearns, GL FC10.2.4, FC13.3.5 Kedia, G Tue 211 Keeble, J Mon 287 Kegeles, L FC17.1.3 Keiko, T Tue 244 Kelber, O Mon 317, Tue 462, Thu 317, Wed 382, Wed 417 Keldsen, N Tue 395 Kelicen, P Wed 438, Mon 155 Keller, M Wed 006 Kelley, S Wed 173 Kellomäki, M Thu 223 Kelly, J Tue 364 Kelstrup, CD Wed 036 Kemeny, A Tue 271, Tue 250, FC16.2.6, Mon 318 Index 341
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293: FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor